conivaptan has been researched along with ganirelix in 1 studies
| Studies (conivaptan) | Trials (conivaptan) | Recent Studies (post-2010) (conivaptan) | Studies (ganirelix) | Trials (ganirelix) | Recent Studies (post-2010) (ganirelix) |
|---|---|---|---|---|---|
| 188 | 17 | 64 | 240 | 92 | 76 |
| Protein | Taxonomy | conivaptan (IC50) | ganirelix (IC50) |
|---|---|---|---|
| Gonadotropin-releasing hormone receptor | Homo sapiens (human) | 0.0036 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for conivaptan and ganirelix
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |